title: Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
abstract: General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany. peter.gruetzmacher@fdk.info.
authors.forename: P
authors.initials: P
authors.lastname: Grützmacher
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Öhm
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Szymczak
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Dorbath
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Brzoska
authors.affiliation: 2nd Medical Clinic - Nephrology, Hypertension and Vascular Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Kleinert
mesh_terms: D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D005858:Germany; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood*; D011322:Primary Prevention / Q000379:methods*; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a)
keywords: Cardiovascular prevention; Lipoprotein (a); Lp (a) apheresis; Target LDL cholesterol